LOTTE BIOLOGICS, under the leadership of CEO James Park, is making significant strides in the global Contract Development and Manufacturing Organization (CDMO) market. The company has recently completed the expansion of its Antibody-Drug Conjugate (ADC) facility at the Syracuse Bio Campus in the U.S., marking a pivotal moment in its growth trajectory. By acquiring Bristol Myers Squibb’s biologics manufacturing facility in New York, LOTTE BIOLOGICS has not only strengthened its manufacturing capabilities but also solidified its position as a key player in the industry.
With investments exceeding USD 100 million, the company has established state-of-the-art ADC production infrastructure, including cutting-edge technology like the SoluFlex Link™ platform. This proprietary technology enhances drug stability and efficacy by improving linker-payload solubility and ADC hydrophilicity, setting LOTTE BIOLOGICS apart in meeting custom ADC production needs. As the company accelerates its global expansion with dual manufacturing bases in North America and Asia, it is poised to lead the way in next-generation biologics and secure integrated competitiveness across facilities and technologies.
Read more on biospace.com